Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: The Dodgy Ticker who wrote (14073)	11/12/2004 11:16:37 PM
From: Biomaven	of 52153

There's some talk about the FDA becoming much more restrictive (i.e., reluctant to approve) new drugs so quickly in the wake of Merck's Vioxx. Do you think that could impact any of the applications you and rkrw are estimating? The FDA has always (rightly) had a "double standard" for drugs depending on their indication. I'd say the safety hurdles for mass-market drugs meant to treat non-serious conditions (or for which there is a reasonable existing alternative) just got higher. But I don't see the FDA becoming tougher on a drug for say cancer therapy or for a drug like Antegren. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next